Mylan CEO Heather Bresch’s defense of her company’s pricing strategies is merely an attempt to deflect blame for setting high drug prices, Pharmaceutical Care Management Association President and CEO Mark Merritt says. “Mylan stands out for its refusal to accept responsibility for its own high prices,” he said. “PBMs, which reduce prescription drug costs by 30% for employers, unions, public programs and the patients they serve, are part of the solution,” Merritt said.